Frontline treatments for older patients with Ph− B-ALL

Acute lymphoblastic leukemia (ALL) represents 5% of all newly diagnosed leukemias in older patients aged 55 to 70 years old. With recent advances...

Why are novel TKIs needed for Ph+ ALL? What does this mean for patients?

During the 63rd ASH Annual Meeting and Exposition, the ALL Hub was pleased to speak with Jorge Cortes, Augusta University,...

AALL1331: blinatumomab improves outcomes for some low-risk pediatric and AYA patients with first relapse of B-ALL

Survival remains poor for first relapse of B-cell acute lymphoblastic leukemia (B-ALL)...

The addition of blinatumomab to the Interfant 06 study protocol for infants with newly diagnosed ALL

Infants (<1 year old) with acute lymphoblastic leukemia (ALL) have worse survival outcomes than...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...

When is it safe to schedule an allo-HSCT after COVID-19 infection?

During the virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

A review of antibody and cellular immunotherapies for adults with relapsed/refractory ALL

The median age of diagnosis of acute lymphoblastic leukemia (ALL) in the United States is 16 years old, making...

AMELIA: A phase 1 trial of CAR T cells with dual CD19 and CD22 targeting in pediatric and young adult patients with R/R B-ALL

Chimeric antigen receptor (CAR) T cells that target CD19 or CD22 have...

Humoral and cellular responses to tisagenlecleucel

Chimeric antigen receptor (CAR) T-cell therapy has elicited high-response rates in patients with relapsed or refractory (R/R) B-cell malignancies...

Brexucabtagene autoleucel approved by the FDA for use in adult ALL

On October 1, 2021, brexucabtagene autoleucel (brexu-cel) became the first chimeric antigen receptor (CAR) T-cell therapy to be...